Places available


Deadline for application



What we need

-MSc in Biology, Biomedicine, Pharmaceutical Sciences or similar

-A high level of motivation and interest

-Excellent level of oral and written English

-Practical experience in molecular and cell biology

-Skills in computational drug design will be positively evaluated 


Main Responsibilities

Successful candidate will be in charge of the preclinical screening of a new family of protein degraders (PROTACs) in different 2D and 3D co-culture models of aggressive B-cell lymphoma. Standard cell and molecular approaches will be carried out to evaluate the efficacy and the safety of this new class of therapeutic compounds in haematological cancers.


What we offer

-Temporary position.

-An exciting and innovative research project.

-Working in the mixed basic and clinical research environment of the Josep Carreras Leukaemia Research Institute.

-Incorporation in a multinational and highly collaborative team.

-The stimulating environment of the Barcelona metropolitan area.

Additional Information

The Josep Carreras Leukaemia Research Institute (IJC) is a non-profit research institute based in Barcelona and dedicated to advancing our understanding about leukaemia and related disorders, in partnership with the University of Barcelona and University Autònoma of Barcelona. The IJC has laboratories in three clinical campuses: i) Clinic Hospital, ii) Sant Pau Hospital and iii) Germans Trias i Pujol Hospital. IJC serves as a collaborative hub for basic investigators and physicians to work together on fundamental biological and clinical aspects of leukaemia. The IJC offers an excellent work environment built around a multi-disciplinary fusion of ideas and state-of-the-art facilities.


Research Description

Aggressive B-cell lymphomas are clinically and pathologically diverse and reflect multiple pathways of transformation involving, among others, oncogenic signaling, lymphoma-stroma crosstalk and intrinsic protein homeostasis. Alterations in these highly regulated processes play a key role in the progression of the malignant clone and correlate with a high failure rate in treatment protocols. In the last decade, new therapies applied to the treatment of B-cell lymphoma have significantly improved the overall survival of these patients, but at present no drug can cure these diseases. At the origin of the gap between promising preclinical results and failure in clinical phase II/III, conventional preclinical models lack predictive value in the main trials carried out in these cancer subtypes. For the design of new therapies more selective and more suited to the biology of these lymphomas, our team focuses on the characterization of new drug targets and on the bench-to-bedside translation of innovative therapeutic strategies, using innovative experimental models of diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and transformed follicular lymphoma (tFL).

Please also visit our unit webpage:


Who we are?

Our mission is to carry out research into the basic, epidemiological, preventive, clinical and translational aspects of leukaemia and other hematologic malignancies.

The vision of the Josep Carreras Leukaemia Research Institute is that research will identify new therapeutic targets and enable us to develop more precise and less aggressive treatments.  We aspire to understand the origin and development of leukaemia and other malignant haematological pathologies in order to be able to prevent them.  We will work for a future in which all leukaemias will be curable.

For further information, please, visit our webpage: and the Josep Carreras non-profit organization:

The European Commission awarded the IJC the HR Excellence seal in July 2019. The IJC continues to work to maintain its policies in line with the Charter and Code principles.

The HRS4R has the main objective of ensuring that research centers of excellence implement and respect the requirements of the European Charter for Researchers and the Code of Conduct for hiring researchers (from here on referred to as the Charter and Code) within their human resources policies.

This EC initiative aims to promote training, professional development, and mobility for all European scientists.  The IJC supports these values and principles, which will not only serve to strengthen its internal policies but will actively stimulate excellent research and firmly situate the organization as an institution with a stimulating working environment that favors the development of its scientists.

IJC is an equal opportunity employer. We evaluate qualified applicants without regard to race, color, religion, sex, national origin, disability, and other legally protected characteristics.

Place of presentation of the candidacies

How to apply

To apply for this opportunity, please send your resume and a cover letter (incl. the contact details of two referees) to jobs@carrerasresearch.orgindicating in the subject of the message: REF.: LT_GR_83.

Deadline for Applications

Please submit your application by October 5th, 2021. 



Related links